Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

The FDA reportedly plans to appoint permanent leaders for CDER and CBER when the White House names its next commissioner nominee. This FDA leadership reset aims to stabilize two centers that shape major drug and biologics decisions. However, pharmaceutical companies
Verseon has challenged one of pharma’s strongest AI drug discovery promises: that data-driven models can consistently create truly novel medicines. In a July 22, 2026 report, the Bay Area drug developer argued that most AI platforms remain tied to known
Explore how Pharma 4.0, smart manufacturing, IoT, artificial intelligence, and digital quality management reshape pharmaceutical operations. This guide explains the GMP controls, data integrity safeguards, validation evidence, and inspection-ready practices companies need for secure digital transformation.
Novo Nordisk filed a federal lawsuit against Eli Lilly in New Jersey on July 21, 2026, accusing the company of misleading consumers through national advertising for Zepbound and Mounjaro. Novo claims Lilly compared its highest drug doses with lower doses
Karen Habercoss, chief information security and privacy officer at the University of Chicago Medicine, warned that hackers and nation-states now use AI to automate and scale cyberattacks. Her warning extends beyond hospitals. In pharma operations, the same technology supporting QA
Computer system validation in pharma helps companies protect electronic records, control GxP risks, and maintain compliance throughout the validation lifecycle. This guide explains risk-based testing, audit trail review, access control, change control, and inspection-ready evidence.
Bristol Myers Squibb announced on July 20, 2026, that it will expand its artificial intelligence infrastructure through a new NVIDIA DGX SuperPOD equipped with Vera Rubin NVL72 systems. BMS plans to use the infrastructure across several research areas, including oncology,
The global market for women-specific cancers could reach $100 billion to $110 billion by 2030, according to a new PwC report. However, achieving that growth will require more than new investment. Pharmaceutical developers, diagnostic manufacturers and regulators must also close